foxo4-dri apoptosis Development of a novel senolytic by precise disruption of FOXO4-p53 complex FOXO4-DRI alleviates age-related testosterone secretion

In clinical trials, the most common adverse effects were gastrointestinal, including nausea, vomiting, diarrhea, and constipation

PMCID: PMC8524106

In rodents, BPC-157s plasma half-life was close to 4 hours after intraperitoneal injection

Inflammatory bowel syndrome Stomach ulcers Bone fractures Injured ligaments, nerves, and muscles Tendinopathies (tendon injuries) like tennis or golf elbow, trigger fingers, or Achilles tendinitis Ulcerative colitis (short bowel syndrome, anastomosis, and fistula) Perforated cecum (part of the large intestine) Post-surgery recovery Spinal cord injuries Arrhythmia (irregular heartbeat) Periodontitis (gum damage) The outcomes for rats may differ from those for humans

Therapeutic potential of BPC 157